{"id":"W2338827745","doi":"10.1093/neuonc/nov206.22","title":"ATCT-22NRG ONCOLOGY/RTOG 1122: PHASE II DOUBLE-BLINDED, PLACEBO-CONTROLLED STUDY OF BEVACIZUMAB WITH OR WITHOUT AMG 386 IN PATIENTS WITH RECURRENT GLIOBLASTOMA OR GLIOSARCOMA","year":2015,"lang":"en","type":"article","venue":"Neuro-Oncology","topic":"Glioma Diagnosis and Treatment","field":"Medicine","cited_by":2,"is_retracted":false,"has_abstract":true,"ca_institutions":"Toronto General Hospital","funders":"","keywords":"Gliosarcoma; Medicine; Bevacizumab; Glioblastoma; Placebo; Double blinded; Oncology; Internal medicine; Phases of clinical research; Clinical trial; Chemotherapy; Pathology; Cancer research","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005460733,0.0007379267,0.002803277,0.0008282851,0.0001507014,0.00002357764,0.0003403193,0.0003638091,0.0001300659],"category_scores_gemma":[0.0002950529,0.0003854449,0.0001363836,0.001100529,0.0002730688,0.0001823154,0.0002442098,0.0006969357,0.00003284819],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001201497,"about_ca_system_score_gemma":0.002059922,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001928712,"about_ca_topic_score_gemma":0.01217454,"domain_scores_codex":[0.9950634,0.0006715429,0.001277807,0.00109279,0.001021644,0.000872825],"domain_scores_gemma":[0.99608,0.0006990894,0.0009117482,0.0009036377,0.0007269394,0.0006786242],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7449375,0.07930946,0.1444554,0.00004624581,0.0007268486,0.004133522,0.003521126,0.00005201823,0.0003350298,0.000009922786,0.001037424,0.0214355],"study_design_scores_gemma":[0.5826774,0.3993918,0.006750833,0.0001306741,0.001105089,0.0003069109,0.001834623,0.0001456176,0.0009779016,0.000003725235,0.00635246,0.0003230444],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874438,0.00008211725,0.000003528515,0.001062598,0.0005095908,0.009665689,0.00002867272,0.0001113709,0.001092611],"genre_scores_gemma":[0.9969897,0.00001785487,0.0003505474,0.0004271296,0.0001380015,0.001871898,0.00003654929,0.0001059382,0.00006241677],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3200823,"threshold_uncertainty_score":0.9998598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04835993962501408,"score_gpt":0.3525851682394304,"score_spread":0.3042252286144164,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}